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ANALISIS KAWALAN KUALITI, PEMIAWAIAN DAN KAJIAN 
KESTABILAN EURYCOMA LONGIFOLIA DAN KESAN KANDUNGAN 
SAPONINNYA TERHADAP KELARUTAN DAN KETOKSIKAN 
EURIKOMANON 
 
ABSTRAK 
Ujian kawalan kualiti dilakukan pada bahan mentah akar, batang dan daun E. 
longifolia daripada lima lokasi yang berbeza untuk menentukan julat nilai kawalan 
kualiti. Kandungan kelembapan, abu dan abu tidak larut asid bagi akar berada di 
dalam julat yang ditetapkan oleh Standard Perubatan Herba Asean dan Monograf 
Herba Malaysia Jilid 1. Julat nilai bagi kawalan kualiti bahan mentah batang dan 
daun telah ditetapkan. Peratusan ekstrak larut air adalah lebih tinggi berbanding 
ekstrak larut alkohol untuk semua bahagian tumbuhan. Peratusan ekstrak yang 
diperolehi dengan kaedah panas adalah lebih tinggi berbanding dengan kaedah sejuk 
untuk kedua-dua ekstrak larut air dan alkohol. Kandungan Pb, Cd, As dan Hg dalam 
bahan mentah E. longifolia didapati berada dalam julat yang diterima Pertubuhan 
Kesihatan Dunia. Kaedah pengekstrakan telah dioptimumkan dengan menggunakan 
nisbah serbuk akar: pelarut dan masa pengekstrakan yang berbeza. Keputusan 
menunjukkan pengeluaran ekstrak yang terbaik ialah pada nisbah serbuk akar: air 
1:15 selama 4 jam setiap kitaran dan diulang sehingga 3 kitaran refluk. Peratusan 
hasil dan profil kimia yang melibatkan analisis kualitatif (HPTLC, UV dan HPLC) 
dan analisis kuantitatif (HPLC) telah dijalankan untuk semua ekstrak. 
 
Kaedah analisis spektroskopi dan kromatografi digunakan untuk pemprofilan 
kimia dan pemiawaian ektrak air bagi akar, batang, daun termasuk enam sampel 
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komersial E. Longifolia berdaftar. Kaedah HPLC memberi peratusan eurycomanone 
bagi akar, batang, daun dan sampel komersial di dalam julat 0.89 ± 0.01% sehingga 
3.28 ± 0.01% , 0.23 ± 0.00% sehingga 1.10 ± 0.00%, 0.10 ± 0.01% sehingga 0.34 ± 
0.02% dan 0.07 ± 0.00% sehingga 0.16 ± 0.00%. Peratusan jumlah fenol, 
glycosaponins, polisakarida dan protein bagi akar adalah masing-masing dari julat 
5.94 ± 0.23% sehingga 10.10 ± 0.08%, 40.12 ± 1.05% sehingga 44.45 ± 0.54%, 
25.30 ± 0.15% sehingga 51.30 ± 2.56% dan 21.42 ± 0.6% sehingga 44.92 ± 2.5%. 
Peratusan jumlah fenol, glycosaponins, polisakarida dan protein bagi batang adalah 
masing-masing dari julat 4.2 ± 0.13% sehingga 8.76 ± 0.3%, 24.09 ± 1.06% sehingga 
47.24 ± 1.07%, 20.53 ± 0.48% sehingga 68.18 ± 0.22% dan 12.17 ± 0.6% sehingga 
48.20 ± 2.0%. Peratusan jumlah fenol, glycosaponins, polisakarida dan protein bagi 
daun adalah masing-masing dari julat 15.88 ± 0.1% sehingga 22.33 ± 0.28%, 52.26 ± 
0.31% sehingga 61.58 ± 0.44%, 7.59 ± 0.04% sehingga 12.59 ± 0.11% dan 58.90 ± 
1.6% sehingga 81.58 ± 2.3%. Peratusan jumlah fenol, glycosaponins, polisakarida 
dan protein bagi sampel komersial adalah masing-masing dari julat 2.53 ± 0.00% 
sehingga 3.34 ± 0.01%, 3.31 ± 0.31% sehingga 16.44 ± 0.21%, 5.98 ± 0.54% 
sehingga 66.17 ± 3.96% dan 6.4 ± 0.2% sehingga 7.8 ± 0.3 %.  
 
Dalam kajian kestabilan dipercepatkan, ekstrak (BR, BS dan BL) adalah lebih 
stabil pada 30ºC berbanding suhu lain yang dikaji dan anggaran hayat (t90) BR, BS 
dan BL adalah 0.31, 0.23 dan 0.36 bulan, masing-masing, pada 30ºC. Eurycomanone 
mempunyai jangka hayat yang lebih panjang dalam ektrak daun (BL) berbanding 
ekstrak akar (BR) dan batang (BS). Penanda sebatian kimia mengikuti degradasi 
tertib pertama dan degradasinya menjadi lebih cepat pada suhu dan kelembapan yang 
lebih tinggi. Oleh itu, untuk jangka hayat yang lebih panjang, adalah disyorkan untuk 
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menyimpan E. longifolia ekstrak pada suhu lebih rendah dari 30ºC di dalam bekas 
yang tertutup rapat. 
 
 Saponins meningkatkan kebolehlarutan eurycomanone melalui pembentukan 
miseles seperti yang ditunjukkan oleh kehadiran zarah sub-mikron. Kepekatan Misel 
Kritikal (CMC) dianggarkan bernilai 267 μg/mL untuk ekstrak air akar mentah (TA), 
57 μg/mL untuk ekstrak kaya saponin dan 847 μg/mL untuk ekstrak kaya 
eurycomanone. Keputusan ini menunjukkan kehadiran miseles dan menunjukkan 
peranan saponin dalam pembentukan miseles, seperti yang ditunjukkan oleh nilai 
CMC rendah dalam ekstrak kaya saponin berbanding dengan nilai CMC ekstrak kaya 
eurycomanone.  Kesan sitotoksik ekstrak kaya eurycomanone terhadap HCT 116 sel 
karsinoma kolorektal menunjukkan kepekatan perencatan median (IC50 ) 22.14 ± 1.0 
μg/mL, manakala ekstrak kaya saponins pada julat kepekatan yang sama tidak 
menunjukkan kesan sitotoksik terhadap sel HCT 116. Kesan sitotoksik gabungan 
ekstrak kaya saponin dan ekstrak kaya eurycomanone terhadap sel HCT 116 telah 
meningkatkan peratusan perencatan, bergantung kepada dos. Didapati bahawa 
dengan penambahan ekstrak kaya saponin dengan ekstrak kaya eurycomanone, kesan 
sitotoksik dapat dikurangkan terutamanya pada ekstrak kaya saponins yang 
berkepekatan rendah (25, 50 dan 75 μg/mL), dan tidak mempunyai kesan pada 
kepekatan tinggi (100 μg / mL). Ini menunjukkan kehadiran saponins di dalam 
ekstrak E. longifolia dapat melindungi kesan sitotoksik eurycomanone. Tambahan 
pula, penemuan yang diperolehi menunjukkan bahawa penggunaan ekstrak mentah 
E. longifolia lebih selamat berbanding penggunaan sebatian tulen atau ekstrak 
eurycomanone pekat. 
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3 QUALITY CONTROL ANALYSIS, STANDARDIZATION AND 
STABILITY STUDIES OF EURYCOMA LONGIFOLIA AND EFFECT OF 
ITS SAPONIN CONTENT ON SOLUBILITY AND TOXICITY OF 
EURYCOMANONE 
 
4 ABSTRACT 
Quality control test was done on E. longifolia root, stem and leaf from five 
different localities in order to determine the range of quality control values. 
Moisture, ash and acid insoluble ash content of all the root raw material were found 
to be within acceptable limit set by Standard of Asean Herbal Medicine and 
Malaysian Herbal Monograph Volume 1. The range of quality control values of the 
stem and leaf raw material have been set. The percentages of water soluble extracts 
were higher as compared to alcohol soluble extracts in all parts of the plant. 
Percentage extractive values by the hot method were higher as compared to the cold 
method for both water and alcohol soluble extracts. The amounts of Pb, Cd, As and 
Hg in E. longifolia raw material were found within acceptable limit according to 
World Health Organization. Extraction method was optimized by different root 
powder: solvent ratio and extraction time. Results suggest the best extraction 
conditions at the root powder: water ratio of 1:15 and at 3 reflux cycles each for 4 h. 
The percentage yield and chemical profile involving qualitative analysis (HPTLC, 
UV and HPLC) and quantitative analysis (HPLC) were carried out for all the 
extracts. 
 
Analytical spectroscopy and chromatographic methods were used for 
chemical profiling and standardization of E. longifolia root, stem, leaf water extracts 
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and six registered commercial products. HPLC validated methods give the 
percentage of eurycomanone for root, stem, leaf and commercial products in a ranges 
0.89 ± 0.01% to 3.28 ± 0.01%, 0.23 ± 0.10% to 1.10 ± 0.00%, 0.10 ± 0.00% to 0.34 
± 0.01% and 0.07 ± 0.00% to 0.16 ± 0.00%, respectively. The percentage of total 
phenolics, glycosaponins, polysaccharides and protein for root ranging from 5.94 ± 
0.23% to 10.10 ± 0.08%, 40.12 ± 1.05% to 44.45 ± 0.54%, 25.30 ± 0.15% to 51.30 ± 
2.56% and 21.42 ± 0.6% to 44.92 ± 2.5%, respectively. The percentage of total 
phenolics, glycosaponins, polysaccharides and protein for stem ranging from 4.20 ± 
0.13% to 8.76 ± 0.30%, 24.09 ± 1.06% to 47.24 ± 1.07%, 20.53 ± 0.48% to 68.18 ± 
0.22% and 12.17 ± 0.6% to 48.20 ± 2.0%, respectively. The percentage of total 
phenolics, glycosaponins, polysaccharides and protein for leaf ranging from 15.88 ± 
0.10% to 22.33 ± 0.28%, 52.26 ± 0.31% to 61.58 ± 0.44%, 7.59 ± 0.04% to 12.59 ± 
0.11% and 58.90 ± 1.6% to 81.58 ± 2.3%, respectively. The percentage of total 
phenolics, glycosaponins, polysaccharides and protein for commercial products 
ranging from 2.53 ± 0.00% to 3.34 ± 0.01%, 3.31 ± 0.31% to 16.44 ± 0.21%, 5.98 ± 
0.54% to 66.17 ± 3.96% and 6.4 ± 0.2% to 7.8 ± 0.3 %, respectively. 
 
In accelerated stability study, extracts (BR, BS and BL) were more stable at 
30ºC compared to other temperatures studied, and the estimated shelf life (t90) of BR, 
BS and BL were 0.31, 0.23 and 0.36 months, respectively, at 30ºC. Eurycomanone 
has higher shelf life in the leaf (BL) as compared to root (BR) and stem (BS). The 
marker compound followed the first order degradation and its degradation rate was 
increased by increasing storage temperature and humidity. Therefore, in order to 
guarantee a longer shelf life of the products, it is recommended to store the products 
containing E. Longifolia extract at below 30ºC in a tightly closed container.  
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Saponins increase the solubility of eurycomanone through the formation of 
micelles as indicated by the presence of sub-micron particles. The Critical Micellar 
Concentration (CMC), was estimated to be 267 µg/mL for the crude root water 
extract (TA), 57 µg/mL for saponins-rich extract and 847 µg/mL for eurycomanone-
rich extract. These results indicate the presence of micelles and show the role of 
saponins in the formation of these micelles as indicated by the lower CMC value in 
saponins-rich extract compared to the CMC value of eurycomanone-rich extract. 
Cytotoxicity effect of eurycomanone-rich extract on HCT 116 colorectal carcinoma 
cells showed dose dependent growth inhibitory effect with median inhibitory 
concentration (IC50) of 22.14 ± 1.0 µg/mL, whereas the saponins-rich extract at the 
same concentration range did not show any cytotoxic effect on the same cells. 
Cytotoxicity effect of combination saponins and eurycomanone-rich extract on HCT 
116 cells was increased in a dose dependent manner. It was found that adding the 
saponins-rich extract to the eurycomanone-rich extract reduced the cytotoxic effect 
of the later particularly at low concentration of the saponins-rich extract (25, 50 and 
75 μg/mL), and has no effect at higher concentration (100 μg/mL). These findings 
indicate that the presence of saponins in the E. longifolia extracts protect against the 
cytotoxic effect of the eurycomanone. Furthermore, these findings indicate that using 
the crude extracts of E. longifolia could be safer than using pure compounds or 
concentrated fractions of eurycomanone.  
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1 CHAPTER 1 
INTRODUCTION 
 
1.1 Significance of Medicinal Plants  
Since historically, medicinal plants have played an important role in human 
life. Plants have been used extensively as food and medicine for the treatment of a 
range of diseases. The sale and use of herbal medicines have increased significantly 
over the past 20 years. The use of herbal medicines in the US increased from 2.5% in 
1990 to 12.1% in 1997, with a total of $5 billion being spent (Eisenberg et al., 1998). 
Within the UK, over 30% of a random sample of 5010 adults were taking, or had 
been taken, herbal remedies (Thomas et al., 2001). Furthermore, 80% of the world's 
population in developing countries depend on the use of herbal and other traditional 
medicines for their primary health care (Khalid et al., 2009). 
 
Medicinal plants are available from a variety of plant material which is from 
leaf, stem, root and bark. They contain many biologically active compounds and can 
be used to treat mild or chronic diseases. Herbs are easy to be obtained, prepared and 
consumed in many ways, using either fresh raw materials or dried ingredients. 
Herbal remedies are also available in the form of capsules, tablets or powder.  
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1.2 Efficacy, Safety and Quality Control in the Standardization of Herbal 
Medicine  
Determination of quality aspects of herbal products can be a problem because 
of the variation in the content and concentrations of constituents of plant material, 
different range of extraction techniques and processing steps used by different 
manufacturers. Many of the herbal products are prepared from a single plant or a 
combination of two or more different types of medicinal plants. It is unusual to have 
different herbal ingredients in one product but the problem is to determine which 
components contribute to biological activities. Pharmacological activities and 
consistency in herbal products are based on chemical constituent’s changes which 
possess the activity of the herbs. To overcome this problem, consistent products can 
be produced through standardization.  
 
 Standardization of herbal materials is carried out to ensure the consistency 
and repeatability of a particular extract in ensuring guaranteed potency through 
acceptable levels of active compounds. This process can be performed by chemical 
(HPTLC, HPLC/GC and FTIR) or biological (antioxidant) analysis. Standardization 
is an important step where the active constituents are known. However, for many 
herbs the active constituents are not known. In these cases, products may be 
standardized on the content of certain ‘marker’ compound (chemical characteristic of 
the herb or present in large quantities). Although there are many benefits proven, 
natural products are not getting wider acceptance in the mainstream of 
pharmaceuticals due to lack of standardization. In order to bring these remedies into 
the mainstream pharmaceutical market, strong scientific evidence is required to 
support the efficacy claims of these products (Barnes, 2003). 
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 Statement that herbal drugs are very safe and free from side effects is not 
absolutely true. The plants contain hundreds of constituents and some are highly 
toxic such as the most cytotoxic anti-cancer plant-derived drugs, digitalis, the 
pyrrolizidine alkaloids, ephedrine, phorbol esters, etc. There are two kinds of side 
effects reported. The first, considered to be intrinsic to herbal drugs themselves, for 
example related to predictable toxicity, over-dosage and interaction with 
conventional drugs, as reported for modern medicines. The most known side effects 
reported for herbal drugs are extrinsic to the preparation for example because of 
several manufacturing problems; misidentification of plants, lack of standardization, 
failure of good manufacturing practice, contamination, substitution and adulteration 
of plants and incorrect preparation or dosage (Calixto, 2000).  
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Due to increasingly widespread use of herbs, it is important to ensure the 
safety of the herbal products. Therefore, the quality control and standardization of 
raw material and the herbal preparation should be permanently conducted. 
Standardization and quality control of herbals is the process involved in the 
evaluation of crude drugs physicochemical aspects such as selection and handling of 
crude material, safety, efficacy and stability assessment of finished products, 
documentation, safety and risk based on experience, provision of product 
information to consumer and product promotion. However, more attention is given to 
the following quality index such as macro and microscopic examination, foreign 
organic matter, ash values, moisture content, extractive values, crude fibre, 
qualitative chemical evaluation, chromatography’s examination, quantitative 
chemical evaluation and toxicological studies (WHO, 1996a; WHO, 1996b; WHO, 
1992).  
 
 Several factors can also affect the quality control and consequently the 
therapeutic value of herbal medicines such as the use of fresh plants, light, 
temperature, nutrients, water availability, duration and time collection, methods of 
collecting, drying, packaging, storage, transportation of raw material, age, part of the 
collected plant and other factors. Method of extraction, contamination with 
microorganism, heavy metals, pesticides and etc, can also affect the quality, safety 
and efficacy of herbal drugs (Calixto, 2000). 
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1.3 Problem Statements and Justification of the Research 
 In Malaysia, dietary supplements are widely consumed for general health and 
well-being and it is easily available in community pharmacies, health food stores, 
night markets, grocery stores and also obtained via the internet. Currently, 183 
products manufactured from E. longifolia are available and registered with the 
National Pharmaceutical Control Bureau (Appendix A). However, there is still a lack 
of information on its chemical profile in the commercial products. All parts (root, 
stem and leaf) of E. longifolia are useful and contributed to different biological 
activities, thus indicating the need to perform quality control tests. The toxic 
potential  of eurycomanone as a major marker compound makes it necessary to 
standardize the plant extracts in commercial products to comply with the set 
standards in order to protect consumers from possible toxic effects. Stability studies 
must be performed in order to estimate the shelf life, suitable temperature storage 
and stability of eurycomanone compound in all parts of the plants. The stability of E. 
longifolia extracts need to comply to ICH standard guidelines. The solubility and 
toxicity of eurycomanone needs improvements. Since saponins are the major primary 
metabolites in this plant, their effect on the solubility and toxicity of eurycomanone 
was investigated. 
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1.4 Objectives of the Study  
The objectives of this study are as the following: 
1. To perform quality control tests on E. longifolia root, stem and leaf raw 
material from five different locations and to optimize the extraction method 
for the root. 
2. To develop and validate reliable analytical methods for chemical profiling 
and standardization of E. longifolia root, stem and leaf water extracts and 
several selected commercial products.  
3. To perform and study the accelerated stability profile of E. longifolia water 
extract of the root, stem and leaf using eurycomanone as a marker. 
4. To study the effect of saponins on the solubility and cytotoxicity of 
eurycomanone-rich extract. 
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2 CHAPTER 2   
LITERATURE REVIEW  
 
2.1 Eurycoma longifolia Jack 
2.1.1 Taxonomy  
Taxonomically, E. longifolia Jack is classified as the following scheme: 
Kingdom: Plantae 
Division: Magnoliophyta 
Class: Magnoliopsida 
Order: Sapindales 
Family: Simaroubaceae 
Genus: Eurycoma 
(Comprehensive information can be found at  
http://en.wikipedia.org/wiki/Eurycoma_longifolia) 
 
2.1.2 Vernacular Names 
 
Some of the common and popular names of this plant includes Long Jack, 
Malaysian Ginseng, Local Ginseng, Natural Viagra, Pasak Bumi, Payung Ali, 
Penawar Pahit, Setunjang Bumi, Bedara Pahit, Tongkat Baginda, Pokok Syurga, 
Tongkat Ali Hitam, Pokok Jelas, Cay ba binh, Ian- don, and Jelaih (Bhat and Karim, 
2010). 
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2.1.3 Plant Description 
E. longifolia Jack is a slender, evergreen flowering tree belongs to the family 
Simaroubaceae, is occurring naturally in jungles of Malaysia and Indonesia. The 
female and male trees reach a height of up to 15 meters (Wernsdorfer et al., 2009)  
and bearing fruits after nearly 2–3 years of cultivation. However, it is generally 
believed that for complete maturation of the plant, it might take up to 25 years. But, 
for commercial uses, most of the times, the roots are harvested after 4 years of 
cultivation. The fruits are green in color, 2–3 cm long and turn to dark red after 
ripening. The leaves are pinnate, spirally arranged, long (10–15 inches) with 10–30 
leaflets. The flowers are produced in large panicles and the plant is dioecious with 
male and female flowers borne on different trees. The plant grows profusely in 
sandy, well-drained soil in the presence of partial shade and with adequate quantity 
of water. This plant is widely sought ‘singly’ or as an ‘essential component’ in herbal 
remedies for a variety of illnesses and as health supplements. Almost all the parts of 
Tongkat Ali have been used traditionally for therapeutic purposes (Bhat and Karim, 
2010). There are four different species of Tongkat Ali, namely Eurycoma longifolia, 
Eurycoma apiculata, Polyathia bullata and Goniothalamus sp. (Aziz et al., 2003). 
Among the four, Eurycoma longifolia is the most commonly used species for the 
extract production (Athimulam et al., 2006).  
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(a)                                
 
                               (b) 
 
                                (c) 
 
                                (d) 
Figure 2.1: Pictures of Eurycoma longifolia (a) - (b) whole plant, (c) leaves and  
(d) root 
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2.1.4 Review of Chemical Constituents of Eurycoma longifolia 
Various chemical constituents have been identified from the different parts of 
E. longifolia. Reviews on the identified chemicals of E. longifolia are summarized in 
Table 2.1. 
Table 2.1: Chemical constituents of Eurycoma longifolia 
Plant 
part 
Extract Chemical constituents References 
Root Aqueous quassinoids (e.g. eurycolactones A-E, 
eurycomalides A-B, eurycomalactone, 
6α-hydroxyeurycomalactone, 7α-
hydroxyeurycomalactone, eurycomanone, 
13α(21)-epoxyeurycomanone, 12,15-
diacetyl-13α(21)-epoxy-
eurycomanone,12-acetyl-13,21-
dihydroeurycomanone, 15-acetyl-
13α(21)-epoxyeurycomanone, 3,4ε-
dihydroeurycomanone, 13,21-
dihydroeurycomanone, eurycomanol, 
13β,18-dihydroeurycomanol, 13β, 21-
dihydroxyeurycomanol, eurycomanol-2-
O-β-D-glycopyranoside, 11-
dehydroklaineanone, 15β-
hydroxyklaineanone, 14,15β-
dihydroxyklaineanone, 5α,14β,15β-
trihydroxyklaineanone,15β-O-acetyl-14-
hydroxyklaineanone, 6α-acetoxy-14,15β-
dihydroxyklaineanone, 6α-acetoxy-15β-
hydroxyklaineanone, laurycolactones A-
B, longilactone, dehydroxylongilactone, 
2,3-dehydro-4α-hydroxylongilactone, 
ailanthone, (α/β-epoxide) ailanthone, 
chaparrinone (α-methyl), 3,4ε-
dihydrochaparrinone, picrasinoside B, 
klaineanolide B, iandonoside B, 
eurycomaoside, 16-α-O-
methylneoquassin, samaderin B and 
glaucarubolone), canthin-6-one alkaloids 
(e.g. canthin-6-one, 9-methoxycanthin-6-
one, 5,9-dimethoxycanthin-6-one, 9,10-
dimethoxycanthin-6-one, 11-
(Chua et al., 2011; 
Chua et al., 2012; 
Yusmazura et al., 
2009) 
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hydroxycanthin-6-one, 1-hydroxy-11-
methoxycanthin-6-one, 10-hydroxy-9-
methoxycanthin-6-one, 11-hydroxy-10-
methoxycanthin-6-one, 11-O-β-D-
glucopyranosylcanthin-6-one, canthin-6-
one-3N-oxide, 9-methoxycanthin-6-one-
3N-oxide and 9-methoxy-3-
methylcanthin-5,6-dione), β-carboline 
alkaloids (e.g. β-carboline-1-propionic 
acid, 7-hydroxy-β-carboline-1-propionic 
acid, 7-methoxy-β-carboline-1-propionic 
acid, and 1-methoxymethyl-β-carboline), 
squalene-type triterpene (e.g. eurylene 
and 11/14-deacetyl eurylene), 
biphenylneolignans (e.g. 2,2’-dimethoxy-
4-(3-hydroxy-1-propenyl)-4’-(1,2,3-
trihydroxypropyl) diphenyl ethers 
(isomer), 2-hydroxy-3,2’,6’-trimethoxy-
4’-(2,3-epoxy-1-hydroxypropyl)-5-(3-
hydroxy-1-propenyl)-biphenyl and 2-
hydroxy-3,2’-dimethoxy-4’-(2,3-epoxy-
1-hydroxypropyl)-5-(3-hydroxy-1-
propenyl)-biphenyl) and others (e.g. 
isoleucine, calcium, magnesium and 
potassium) 
 
  Methanol quassinoids (e.g. eurycolactones A-F, 
eurycomalides A-B, eurycomalactone, 
6α-hydroxyeurycomalactone, 6-hydroxy-
5,6-dehydroeurycomalactone, 5,6-
dehydroeurycomalactone, eurycomanone, 
13β,21-dihydroxyeurycomanol, 14,15β-
dihydroxyklaineanone, 5α,14β,15β-
trihydroxyklaineanone, laurycolactones 
A-B, longilactone, 6-
dehydroxylongilactone, 2,3-dehydro-4α-
hydroxylongilactone and pasakbumin B-
C), canthin-6-one alkaloids (e.g. canthin-
6-one, 1-hydroxycanthin-6-one, 9-
hydroxycanthin-6-one, 5-
hydroxymethylcanthin-6-one, 5-
methoxycanthin-6-one, 9-
methoxycanthin-6-one, 10-
methoxycanthin-6-one, 1-hydroxy-9-
(Kardono et al., 
1991;  
Chan et al., 1991; 
Chan et al., 1992; 
Ang et al., 2000; 
Ang et al., 2002; 
Kuo et al., 2003b; 
Teh et al., 2010; 
Kuo et al., 2003a) 
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methoxycanthin-6-one, 4-hydroxy-5-
methoxycanthin-6-one, 8-hydroxy-9-
methoxycanthin-6-one, 5-
hydroxymethyl-9-methoxycanthin-6-one, 
4,5-dimethoxycanthin-6-one, 9,10-
dimethoxycanthin-6-one, canthin-6-one 
9-O-β-glucopyranoside, canthin-6-one-
3N-oxide, 9-hydroxycanthin-6-one-3N-
oxide and 9-methoxycanthin-6-one-3N-
oxide), β-carboline alkaloids (e.g. β-
carboline-1-propionic acid, 7-methoxy-β-
carboline-1-propionic acid, methyl β-
carboline-1-carboxylate, n-pentyl β-
carboline-1-propionate and picrasidine 
L), triterpenes (e.g. eurylene,  mixture of 
β-sitosterol and stigmasterol, and β-
sitosteryl glucoside) and others (e.g. 
scopoletin, fraxidin, scopolin, ρ-
hydroxybenzaldehyde, syringic aldehyde, 
2,4’-dihydroxy-3’-methoxyacetophenone, 
2,3-dihydroxy-1-(4’-hydroxy-3’-
methoxyphenyl)-propan-1-one, 3-
hydroxy-1-(4’-hydroxy-3’-
methoxyphenyl)propan-1-one, threo-1,2-
bis-(4-hydroxy-3-
methoxyphenyl)propane-1,3-diol, vanillic 
acid, protocatechuic acid, nicotinic acid, 
syringic acid, sodium syringate, sodium 
ρ-hydroxybenzoate, lariciresinol, erythro-
1-C-syringylglycerol, threo-1-C-
syringylglycerol, erythro-
guaiacylglycerol, threo-guaiacylglycerol, 
iandonone, adenosine, guanosine, 
thymidine, alanine, proline, arginine, 
serine, glucose and fructose). 
 
 Ethanol 
(50%) 
quassinoids (e.g. eurycomanone, 13,21-
dihydroeurycomanone, 13α(21)-
epoxyeurycomanone, longilactone, 
eurycomalactone, 14,15β-
dihydroxyklaineanone, eurycomanol, 
eurycomanol-2-O-β-glucopyranoside) 
and a canthin-6-one alkaloid (e.g. 9-
methoxycanthin-6-one).] 
(Chan et al., 1989; 
Chan and Choo, 
2002;  
Chan et al., 2004) 
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 Aqueous 
and 
Methanol 
Volatile components were also detected 
in the aqueous and methanol root 
extracts, e.g. 3-methylbutanal, 1-butanol, 
1-pentanol, 2-hexadecanol, acetol, 
nonanal, acetic acid, 2-methylhexanol, 
benzaldehyde, -2,3-butanediol, 
butyrolactone, 2-furanmethanol, 3-
methylbutanoic acid, 2(5H)-furanone, 
curcumene, hexanoic acid, butylated 
hydroxytoluene, 1-(1H-pyrrol-2-yl)-
ethanone, (R)-(−)-massoilactone, 1H-
pyrrole-2-carboxaldehyde, 3-phenoxy-1-
propanol, octanoic acid, [1R,2S,5R]-1’-
[butyn-3-one-1-yl]-menthol, 2-
phenoxyethanol, ethyl p-ethoxybenzoate, 
nonanoic acid, 4-ethynyl-4-hydroxy-
3,5,5-trimethyl-2-cyclohex-1-enone, 2,4-
bis(1,1-dimethylehtyl)phenol, diethyl 
phthalate, benzoic acid, 2,3,6,7-
tetrahydro 4a,8a-butano-[1,4]dioxino[2,3-
b]-1,4dioxin. 
 
(Shafiqul et al., 
2006) 
Leaves Ethanol Quassinoids (lonilactone, 6-dehydro 
lonilactone,11-dehydroklaineanone, 12-
epi dehydroklaineanone, 15β-
hydroxyklaineanone, 14,15 β-
dihydroxyklaineanone, and 15-β-O-
acetyl-14-hydroxyklaineanone) 
 
(Jiwajinda et al., 
2001) 
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Figure 2.2: Chemical structure of Eurycomanone 
 
 
 
2.1.5 Review of Pharmacological Activities of Eurycoma longifolia 
E. longifolia Jack (Tongkat Ali) is one of the most popular herbs in Malaysia. 
This plant is a symbol of man’s ego and strength because it has been claimed by 
Malaysians to improve strength and power during sexual activities; it increases male 
virility and sexual prowess and is usually taken as a decoction of the roots in water 
(Gimlette and Thomson, 1977). The root has also been traditionally used for fever, 
afterbirth medication, boils, wounds, ulcer, syphilis, bleeding gums, ache, dysentery, 
glandular swelling, oedema and tonic (Gimlette and Burkill, 1930; Burkill and 
Haniff, 1930). The leaves of the plant have been used by traditional healers to cure 
malaria, ulcers, prevent gum diseases and for the treatment of sexually transmitted 
diseases such as syphilis and gonorrhoea (Bhat and Karim, 2010).  
 
E. longifolia is reported to have many pharmacological activities. 
Antimalarial activity of E. longifolia has been investigated by several studies. 
Eurycomanone, pasakbumi B and 7-methoxy--carboline-1-propionic acid isolated 
from E. longifolia root exhibited potent anti-plasmodial activity against                    
P. falciparum (Chan et al., 1986). In another study, it was shown that eurycomanone, 
13,21 dihydroeurycomanone, 13α(21)-epoxyeurycomanone, eurycomalactone, and 9-
methoxycanthin-6-one isolated from 50% aqueous ethanol root extracts displayed 
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anti-plasmodial activity against chloroquine-resistant Gombak A isolate of               
P. falciparum with IC50 in the range of 0.23-1.56 µg/mL (Chan et al., 2004). A 
mixture of semi-purified root extract (13β,18-dihydroeurycomanol, eurycomanol-2-
О-β-D-glucopyranoside, eurycomanol and eurycomanone) of 0.07-5.00 µg/mL 
demonstrated more than 50% inhibition of P. falciparum strain (Kuo et al., 2004; 
Ang et al., 1995). The standardized methanol extract of E. longifolia root at the 
concentration of 10, 30 and 60 mg/kg BW in combination with artemisinin given 
orally to mice for 3 days showed suppression of 63, 67 and 80% of Plasmodium 
yoelii infection in mice, respectively, whilst 80% suppression of P. yoelii infection 
was observed with subcutaneous treatment of E. longifolia (10 mg/kg BW) combined 
with artemisinin (Mohd et al., 2007). 
 
Cytotoxicity of E. longifolia has been reported in many studies. 
Eurycomanone isolated from E. longifolia roots exhibited potent cytotoxicity with 
IC50 values of 45 ± 0.15 μg/mL of hepatoma (HepG2) cells through apoptosis 
mechanism (Yusmazura et al., 2009). In another study, Eurycomalactone, 6-
dehydroxylongilactone, 9-methoxycanthin-6-one, canthin-6-one, longilactone, 
14,15β-dihydroxyklaineanone, pasakbumin C and canthin-6-one 9-O-β-
glucopyranoside isolated from E. longifolia roots exhibited potent cytotoxicity 
towards human lung cancer (A549) cell lines with ED50 in the range of <2.5 to 4.6 
µg/mL,  while eurycomalactone, 6-dehydroxylongilactone, 9-methoxycanthin-6-one, 
14,15β-dihydroxyklaineanone, eurycomanone, pasakbumin B and pasakbumin C 
exhibited potent cytotoxicity towards human breast cancer MCF-7 cells (ED50 <2.5-
4.5 µg/mL) (Kuo et al., 2004). 9-methoxycanthin-6-one, 9-methoxycanthin-6-one-N-
oxide, 9-hydroxycanthin-6-one and 9-hydroxycanthin-6-one-N-oxide isolated from 
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E. longifolia roots exhibited cytotoxic effects against human cancer cell types 
including breast, colon, fibrosarcoma, lung, melanoma, KB and murine lymphocytic 
leukemia (P-388) with ED50 in the range of 1.4 to 11.7 µg/mL. Eurycomanone was 
active against all cells above including vincristine-resistant KB cells (ED50 0.2-11.3 
µg/mL), except P-388 cells  (Kardono et al., 1991). A different study reported that 
eurycomanone, 21-dihydroeurycomanone and 14,15β-dihydroxyklaineanone from    
E. longifolia roots showed a potent cytotoxic effect against KB cells with IC50 values 
of 0.98, 0.81 and 0.96 µM, respectively (Chan et al., 2004). 
 
Many studies reported the effect of aphrodisiac activity in E. longifolia. 
Aqueous extract of E. longifolia root (30, 60, 90, 150 mg/kg) given via oral gavage 
to Sprague Dawley male rats for 28 days enhanced sexual activities and sperm 
quality (sperm count, motility, morphology and viability) of the treated rats. In 
another study, chloroform, methanol, butanol and water fractions of E. longifolia root 
given orally to 3-4 month old male Sprague Dawley albino rats for 10 days showed a 
dose-dependent increase in mounting frequency from 5.3 (400 mg/kg) to 5.4 (800 
mg/kg), 4.9 to 5.4, 4.8 to 5.2 and 5.2 to 5.3, respectively (Ang and Sim, 1997). These 
fractions (500 mg/kg) contributed towards sexual motivation activity in adult, 
middle-aged male albino mice and in retired breeders (Ang et al., 2003a), as well as 
enhanced sexual qualities of middle-aged male rats (Ang et al., 2003b). Different 
studies reported that methanol, chloroform, water and butanol fractions of E. 
longifolia root (800 mg/kg) given via oral gavage to 9-month old Sprague Dawley 
rats for 10 days showed changes in sexual behaviour such as increased orientation 
activities towards the receptive female rats (anogenital sniffing, licking and 
mounting), increased genital grooming towards themselves and restricted movements 
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to a particular area of the cage (Ang and Lee, 2002). The fractions (800 mg/kg) were 
also found to promote sexual arousal in sexually sluggish old male rats (Ang et al., 
2004). Additionally, these fractions (800 mg/kg) given orally for 12 weeks to 
testosterone-stimulated castrated intact male rats revealed pro-androgenic property as 
evidenced by the enhanced growth of the laevator ani muscle (Ang and Cheang, 
2001). 
 
Anti-diabetic property of E.longifolia was reported. In this study, 
antihyperglycaemic activity of aqueous extract of E. longifolia root (150 mg/kg body 
weight) was observed in streptozotocin-induced hyperglycaemic Sprague Dawley 
rats after 10 days of treatment (Husen et al., 2004). 
 
Anxiolytic activity effect of E. longifolia was investigated. The result showed 
that chloroform, methanol, butanol and water fractions of E. longifolia root (0.3 
g/kg) was administered by oral gavage to inbred adult albino mice (35-40 g) exerted 
anxiolytic effect (Ang and Cheang, 1999). 
 
The effect of E.longifolia on anti-osteoporosis was investigated. In this study, 
supplementation of E. longifolia root aqueous extract given to 12-month old 
orchidectomised Sprague Dawley rats for 6 weeks showed maintenance of bone 
calcium level (Shuid et al., 2011). 
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2.2 Stability Studies 
Stability is defined as the time during which a drug to maintains its chemical 
integrity and labelled potency within the certain limits. The stability of a 
pharmaceutical preparation is its degree of resistance to chemical and physical 
changes. Products should be consistent in its effectiveness and claimed potency or 
may change only within the limits set by the legal provisions until the expiration date 
(Racz, 1989). Stability is one of the most important factors that determine whether a 
compound or mixture of compounds can be developed into a pharmaceutical product. 
Stability studies provide evidences on how the quality of a drug substance varies 
with the passage of time under the influence of environmental factors (WHO, 1996). 
Stability studies before developing a dosage form are the first quantitative 
assessment of chemical stability of a new product and its possible formulation. 
Stability studies are used to recommend storage conditions and predict shelf life of 
medicinal products. 
 
The stability studies are important for three main reasons. Firstly, it is for the 
patient safety by making sure that the patient receives a uniform dose of drug 
throughout the whole shelf life of the product. Even though a drug may have been 
shown to be safe for use, this is not necessarily true for the decomposition products. 
Secondly, consideration must be given to the relevant legal requirements concerned 
on the identity, strength, purity and quality of the drug. Finally, stability study is 
important to prevent the economic impact of marketing an unstable product. The 
stability of a product is influenced by a number of factors, which may be classified 
into two main categories, physical and chemical factors.  
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2.2.1 Physical Factors Effecting Stability 
2.2.1.1 Temperature 
Temperature increases the rate of degradation of active ingredients due to the 
increase in kinetic energy, which increases the number of colliding molecules. The 
decomposition normally increases by two to three times for every 10°C temperature 
rises. Therefore, it is important to be aware of it while keeping raw material and in 
production of a product especially when heating is required. It is important especially 
in the case of thermo labile and volatile constituents. 
 
2.2.1.2 Moisture 
Moisture content increases the rate of decomposition and makes the product 
susceptible to hydrolysis. For raw herbal powders or extract, it allows the growth of 
microbes that not only deteriorate the constituents but can produce toxic substances. 
 
2.2.1.3 Light 
Sunlight as an energy form can initiate and accelerates decomposition. Photo 
labile constituents of extracts deteriorate on expose to sunlight (Rawlins, 1977; Pugh, 
2002). 
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2.2.2 Chemicals Factors Effecting Stability 
The constituents of extracts also undergo chemical degradation over the time. 
The chemical degradation is further classified as follows: 
 
2.2.2.1 Hydrolysis 
Hydrolysis, reaction of the substance with water is the most common cause of 
drug degradation (Waterman et al., 2002). It is considered as the main cause of 
deterioration of drugs, especially for aqueous-based preparations. 
 
2.2.2.2 Oxidation 
Oxidation is defined as the removal of an electropositive atom, radical or 
electron, or addition of an electronegative atom, radical or electron. Decomposition 
of pharmaceutical preparation due to oxidation is nearly as probable as that of 
hydrolysis. The rate of oxidation is depends on the temperature. For example, 
peroxidation of fatty acids, break down of fatty acids into aldehydes and ketones, 
accelerates as the temperatures exceeds 50°C (Rawlins, 1977). 
 
2.2.2.3 Isomerisation and Polymerization 
Polymerization is defined as the addition of similar molecules whereas 
isomerisation is the change in isomeric forms. These phenomena change the 
biological activity of compounds. 
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2.2.3 Accelerated Stability 
The stability study of pharmaceuticals performed at exaggerated conditions is 
called accelerated stability. The accelerated stability study is performed for fast 
prediction of stability. Degradation is usually slow at room temperature and shelf life 
may go up to several years. Stability testing for this type will be time consuming and 
expensive since the period can be as long as two years. Therefore, accelerated 
stability testing is devised for rapid prediction of long term stability of a product. The 
stability of drugs at room temperature is the main purpose of this study but it would 
take a long time to conduct. Therefore, stability studies are conducted at elevated 
temperatures and the data is evaluated by applying Arrhenius equation 
(Sungthongjeen, 2004). 
 
 An estimation of shelf life (t90), a time in which a product retains 90% of its 
original potency, may be made by accelerating the decomposition process and 
extrapolating the results to normal storage conditions. Therefore, stability tests are 
often conducted under elevated temperatures to accelerate the degradation process in 
order to get a fast stability prediction. Application of the principles of chemical 
kinetics on the results of accelerated stability tests enables us to make prediction and 
estimate the shelf life of a product at normal temperature.  
 
 
 
 
 
 
22 
 
2.3 Saponins 
2.3.1 Definition and Chemical Compositions 
'Saponin' name is derived from the Latin word sapo, which means 'soap', 
because saponin molecules form a soap- like foams when shaken with water 
(Vincken et al., 2007). Saponins are found in great number of plant species and 
usually found in roots, tubers, leaves, blooms or seeds. Saponins can be classified 
into two groups based on the nature of their aglycone skeleton. The first group 
consists of the steroidal saponins and the second group consists of the triterpenoid 
saponins.  Steroidal saponins consist of a steroidal aglycone, a C27 spirostane 
skeleton, generally comprising of a six-ring structure (Figure 1.1 (a)). Triterpenoid 
saponins consist of a triterpenoid aglycone, which consists of a C30 skeleton, 
comprising of a pentacyclic structure (Figure 1.1 (b)) (Sparg et al., 2004).  
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Figure 2.3: Aglycone skeletons of (a) steroidal spirostane and (b) triterpenoid 
saponins. R = sugar moiety 
 
2.3.2 A Review of the Pharmacological Activities of Saponins 
Pharmacological activities of saponins have been reported in several studies. 
Haemolytic activity in a mixture of saponins isolated from Maesa lanceolata Forssk. 
(Myrsinaceae) was reported. In this study, the maesasaponin mixture showed very 
high haemolytic activity, haemolysing 50% of the human erythrocytes (1% 
suspension in phosphate buffer saline) at a concentration of 1.6 µg/mL (Sindambiwe 
et al., 1998). 
 
The Molluscicidal activity of saponins has been reported in many studies. A 
six-oleanane-type triterpenoid saponin mixture (maesasaponin mixture, isolated from 
Maesa lanceolata) was tested for molluscicidal activity against Biomphalaria 
glabrata snails. The saponin mixture showed high toxicity, with LD95 and LD50 
values of 4.1 and 2.3 µg/mL, respectively (Sindambiwe et al., 1998). In another 
a 
b 
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study, the biodegradability of molluscicidal water-extracted saponins from the 
berries of Phytolacca dodecandra was reported. From the study, the saponins in an 
aqueous extract of Phytolacca dodecandra readily biodegraded (t1/2 = 15.8 h) when 
consumed within 10 days in aquatic environments under aerobic conditions.  As a 
result, the use of Phytolacca dodecandra berries for snail control in schistosomiasis 
infested water bodies are environmentally acceptable (Mølgaard et al., 2000). One of 
the ten isolated saponins from the leaves of Maesa lanceolata showed molluscicidal 
activity against Biomphalaria glabrata snails. Maesasaponin VI2 is responsible for a 
large part of the activity of the mixture. This saponin had a LC50 value of 0.5 
mg/mL in its isolated form (Apers et al., 2001). 
 
The effect of anti-inflammatory activity of saponins has been reported by 
several studies. Fruticesaponin B, a bidesmosidic saponin with an unbranched 
saccharide moiety isolated from Bupleurum fruticescens L. (Apiaceae), was shown to 
have the highest anti inflammatory activity of the all the saponins tested in the mouse 
oedema assays (Just et al., 1998). Saponins isolated from Bupleurum rotundifolium 
L. (Apiaceae) were reported to have anti-inflammatory activity against both 12-O-
tetradecanoylphorbol-13-acetate (TPA) induced ear oedema and chronic skin 
inflammation (Navarro et al., 2001) Kalopanaxsaponin A and pictoside A, both two 
isolated triterpenoid saponins from the stem bark of Kalopanax pictus Nakai 
(Araliaceae) showed significant anti-inflammatory activity at the oral dose of 50 
mg/mL (Li et al., 2002).   
 
 
